BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 18222534)

  • 1. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
    Kalli KR; Oberg AL; Keeney GL; Christianson TJ; Low PS; Knutson KL; Hartmann LC
    Gynecol Oncol; 2008 Mar; 108(3):619-26. PubMed ID: 18222534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of folate receptor alpha in ovarian epithelial tumors].
    Shen DH; Xie JL; Zhang YL; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
    Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
    Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
    BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
    Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
    Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome in serous ovarian cancer is not associated with LATS expression.
    Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
    Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
    Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
    Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
    Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
    World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.
    Sanada S; Futami K; Terada A; Yonemoto K; Ogasawara S; Akiba J; Yasumoto M; Sumi A; Ushijima K; Kamura T; Furuichi Y; Yano H
    PLoS One; 2013; 8(8):e72820. PubMed ID: 23951333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
    Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
    Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
    Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.